Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesThe transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis
Rheumatology, 06/26/09
Solanilla A et al. – Study demonstrates that platelets transport high levels of VEGF in systemic sclerosis (SSc); may contribute to circulating VEGF because of ongoing activation in the course of the disease. If activated at the contact of injured endothelium, platelets may be important in the altered angiogenesis.
Methods- An investigation of platelet activation and the role of platelets as a source of VEGF and other angiogenic mediators in SSc
- 40 patients with SSc; age- and sex-matched healthy subjects and subjects presenting a primary RP as controls
- Platelets were isolated, activated with thrombin and the secretion of VEGF, PDGF, homodimeric form BB (PDGF-BB), TGF-β1 and angiopoietins-1 and -2 measured
- Plasma concns of these mediators and the functionality of platelet-derived VEGF were also studied
- Platelet activation was assayed by measuring plasma β-thromboglobulin and expression of P-selectin on platelets
- The effect of iloprost on VEGF secretion by platelets was studied
- Platelets from SSc pts, vs controls, secreted large amounts of VEGF when activated, but not PDGF-BB, TGF-β1 or angiopoietins
- Increased expression of membrane P-selectin confirmed platelet activation in the pts
- Iloprost inhibited VEGF secretion by platelets both in vivo and in vitro, through inhibition of platelet activation
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Sponsor
Article Search
Sponsor
Sponsor